1 / 15

Thrombolytic Agents

Thrombolytic Agents. Benedict R. Lucchesi, M.D., Ph.D. Department of Pharmacology University of Michigan Medical School. Thrombolytic Therapy. Streptokinase Tissue Plasminogen Activator (rt-PA) Urokinase Retavase Tenecteplase, TNK-tPA ( TNKase™). Anticoagulant Therapy Thrombolysis.

hada
Télécharger la présentation

Thrombolytic Agents

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Thrombolytic Agents Benedict R. Lucchesi, M.D., Ph.D. Department of Pharmacology University of Michigan Medical School

  2. Thrombolytic Therapy • Streptokinase • Tissue Plasminogen Activator (rt-PA) • Urokinase • Retavase • Tenecteplase, TNK-tPA ( TNKase™)

  3. Anticoagulant Therapy Thrombolysis

  4. The primary action of all thrombolytic agents is to convert plasminogen to plasmin. Plasmin possess enzymatic activity that brings about the degradation of fibrin (fibrinolysis) that results in clot lysis.

  5. Thrombolytic Therapy • The plasminogen molecule contains structures called LYSINE-BINDING SITES (kringles). • The lysine-binding sites bind plasminogen to fibrin. • The inactive pro-enzyme, plasminogen, is associated with the fibrin in the thrombus or blood clot. • The lysine-binding sites play an important role in regulating FIBRINOLYSIS.

  6. Thrombolytic Therapy PLASMIN has the ability to “digest” FIBRIN to soluble degradation products. The blood contains two physiologically active plasmin-ogen activators: 1. Tissue type plasminogen activator 2. Single-chain urokinase-type plasminogen activator In addition there are two inhibitors of the fibrinolytic system present in blood: 1. Plasminogen activator inhibitor - 1 2. alpha-2 - antiplasmin

  7. StreptokinaseNonenzyme protein produced by several strains of hemolytic streptococci.

  8. Streptokinase • INDIRECTLY activates plasminogen (Plg) to plasmin Pl) in 3 steps. • Step 1 Streptokinase forms an equimolar complex with plasminogen (Plg-SK complex). The conformational change takes place in plasminogen and exposes an “active site” • Step 2 Active site catalyzes the activation of plasminogen (Plg) to plasmin (Pl) • Step 3 Plg-SK is converted to Pl-SK

  9. Streptokinase • Plasma half-life of 20 min • Neutralized by anti-streptokinase antibodies due to previous infections with ß-hemolytic streptococci • Anti-streptokinase titer increases 50 - 100 times within a few days after administration, remains high for 4 - 6 months • Repeated therapy within this time is impractical

  10. Tissue Plasminogen Activator Facts about t-PA • it shows a specificity for fibrin • activation of plasminogen is 2 to 3 orders of magnitude greater when plasminogen is bound to fibrin. • plasmin is formed on the fibrin surface within the clot. • plasmin bound to fibrin is protected from the rapid inactivation of its enzymatic activity. • free plasmin in the plasma has a t 1/2 of 0.1 seconds as compared to plasmin that is bound to fibrin (10 to 100 secs). • rt-PA (Alteplase; Activase™) approved for use in: myocardial infarction and stroke.

  11. Guidelines for use of rt-PA in stroke - 2 • Thrombolysis is not recommended unless the proper diagnosis (with CT of the brain) made by physicians expert in diagnosing stroke and reading CT. • Avoid thrombolysis where there is evidence of recent major infarction, mass effect, edema or possible hemorrhage, on heparin in the last 48 hrs or warfarin or with a platelet count <100,000. • Patients treated with rt-PA for stroke, should not be given aspirin, ticlopidine, clopidogrel, heparin, or warfarin.

  12. Comparative Pharmacologic Features Feature SK APSAC UK SCUPA rtPA Half-Life (min) 23 90 16 7 5 Fibrin-Selective + + ++ ++++ +++ Duration of Infusion 60 min 2-5 m 5-15 m Hours Hours Antigenicity Yes Yes No No? No? Incidence of Reperfusion (%) 60-70 60-70 60-70 60-70 60-70 Frequency of Reocclusion (%) 15 10 10 NA 20 Fibrinogenolysis ++++ ++++ +++ ++ ++ Platelet Activation +++ +++ 0 ? ++++

  13. Tenecteplase TNK-tPA (TNKase™) • Acts more rapidly than t-PA, has more rapid plasma clearance, shorter half-live (11-19 min). • More convenient administration - 10 U over <2 min followed in 30 min by a second iv bolus.

  14. Tenecteplase TNK-tPA (TNKase™) • Description: • tenecteplase is a bio-engineered plasminogen activator, • tenecteplase is also known as TNK-tPA. "TNK" refers to the sites of the tPA molecule that have been modified (T103N, N117Q, KHRR 296—299 AAAA). • Actions: • tenecteplase is a variant of tPA. • tenecteplase reduces fibrinogen by 5—10% and plasminogen by 10—15%, compared to decreases of 40% and 50%, respectively, for alteplase; because of this, TNK-tPA may be more fibrin specific than alteplase.

  15. Tenecteplase TNK-tPA (TNKase™) • Uses: • for the treatment of acute MI. • Distinguishing Features: • compared to alteplase, tenecteplase has a prolonged half-life (alpha half-life 11—20 min; beta half-life 41—138 min), increased specificity for fibrin, and increased resistance to plasminogen activator inhibitor-1 (PAI-1) • its main advantage might be that it can be administered as a single IV bolus injection.

More Related